Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Other Non-Current Liabilities (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 2.53% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 2.53% decrease, with the full-year FY2024 number at $1.3 million, down 14.97% from a year prior.
  • Other Non-Current Liabilities was $1.5 million for Q3 2025 at Harvard Bioscience, up from $1.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $2.8 million in Q1 2021 to a low of $418000.0 in Q2 2022.
  • A 5-year average of $1.4 million and a median of $1.4 million in 2025 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: surged 230.39% in 2021, then plummeted 83.53% in 2022.
  • Harvard Bioscience's Other Non-Current Liabilities stood at $486000.0 in 2021, then soared by 107.0% to $1.0 million in 2022, then surged by 46.72% to $1.5 million in 2023, then decreased by 14.97% to $1.3 million in 2024, then increased by 16.57% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Other Non-Current Liabilities are $1.5 million (Q3 2025), $1.4 million (Q2 2025), and $1.4 million (Q1 2025).